BioMark Diagnostics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Rashid Ahmed Maula Bux
- Full Time Employees
- 9
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 3851 Shell Road Richmond BC Canada V6X 2W2
- IPO Date
- Nov 3, 2014
- Website
- biomarkdiagnostics.com
- Similar Companies
- Business
- BioMark Diagnostics Inc. (CSE: BUX) develops and commercializes liquid biopsy diagnostic technologies leveraging metabolomics and machine learning for early-stage cancer detection, monitoring, treatment response assessment, and survivor surveillance; its core offerings include proprietary blood-based assays targeting hard-to-detect carcinomas such as lung cancer via biomarkers like Spermidine/spermine N-acetyltransferase 1 (SSAT1), high-powered metabolic panels for non-invasive screening, and advanced molecular diagnostic services for oncology research and clinical applications. The company operates primarily in the biotechnology and medical diagnostics sector, serving oncologists, healthcare providers, pharmaceutical firms, and biotechnology partners with a focus on North American and international markets including Canada, the United States, Quebec, and Europe. Founded in 2014 and headquartered at 3851 Shell Road, Suite 130, Richmond, British Columbia, Canada, BioMark advances its platform through collaborations with academic institutions, cancer centers, and regulatory experts. In recent developments, BioMark completed a CAD $4.26 million private placement in fiscal year 2025 with participation from North American and European investors, alongside over CAD $365,000 in non-dilutive grants from entities including NRC-IRAP, Mitacs, Research Manitoba, and the City of Quebec to support commercialization efforts. The company expanded its specialty laboratory services in Quebec in August 2025 through a strategic equipment leasing agreement that doubled testing capacity, introduced state-of-the-art capabilities, and accelerated the launch of its lung cancer assay while enhancing research services for metabolomics clients. Additional milestones include uplisting to the OTCQB Venture Market in May 2025 to boost U.S. investor access and liquidity ahead of U.S. expansion, ongoing discussions for international partnerships, licensing opportunities, and non-dilutive funding as of September 2025, and progress toward regulatory approvals for broader clinical deployment.
Company News
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark: 2025 Achievements & 2026 Vision
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
BioMark Diagnostics using biomarkers for early cancer detection to save lives, healthcare resources
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test